Kane Biotech Inc. (KNE.V)
CAD 0.1
(0.0%)
CAD 0.1
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 3.46 Million CAD | -27.43% |
| 2022 | 4.77 Million CAD | -12.38% |
| 2021 | 5.45 Million CAD | 14.75% |
| 2020 | 4.75 Million CAD | 13.12% |
| 2019 | 4.2 Million CAD | 27.5% |
| 2018 | 3.29 Million CAD | -8.69% |
| 2017 | 3.6 Million CAD | 34.11% |
| 2016 | 2.69 Million CAD | 49.99% |
| 2015 | 1.79 Million CAD | 16.06% |
| 2014 | 1.54 Million CAD | -4.05% |
| 2013 | 1.61 Million CAD | 10.02% |
| 2012 | 1.46 Million CAD | 18.51% |
| 2011 | 1.23 Million CAD | 32.91% |
| 2010 | 929.4 Thousand CAD | 6.78% |
| 2009 | 870.35 Thousand CAD | -17.13% |
| 2008 | 1.05 Million CAD | -0.19% |
| 2007 | 1.05 Million CAD | 17.89% |
| 2006 | 892.58 Thousand CAD | -13.77% |
| 2005 | 1.03 Million CAD | 68.05% |
| 2004 | 615.97 Thousand CAD | 27.75% |
| 2003 | 482.18 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 1.21 Million CAD | 5165.49% |
| 2024 Q2 | 1.46 Million CAD | 20.27% |
| 2023 FY | 3.69 Million CAD | -22.67% |
| 2023 Q1 | 1.36 Million CAD | 55.64% |
| 2023 Q2 | 866.22 Thousand CAD | -36.34% |
| 2023 Q4 | 23.1 Thousand CAD | -98.47% |
| 2023 Q3 | 1.51 Million CAD | 74.68% |
| 2022 Q3 | 1.12 Million CAD | -17.63% |
| 2022 Q4 | 874.29 Thousand CAD | -22.03% |
| 2022 Q2 | 1.36 Million CAD | -4.14% |
| 2022 Q1 | 1.42 Million CAD | -4.74% |
| 2022 FY | 4.77 Million CAD | -12.38% |
| 2021 Q1 | 1.14 Million CAD | -1.62% |
| 2021 Q3 | 1.72 Million CAD | 57.86% |
| 2021 Q4 | 1.49 Million CAD | -13.4% |
| 2021 Q2 | 1.09 Million CAD | -5.15% |
| 2021 FY | 5.45 Million CAD | 14.75% |
| 2020 Q2 | 711.44 Thousand CAD | -56.2% |
| 2020 Q4 | 1.16 Million CAD | -6.31% |
| 2020 Q3 | 1.24 Million CAD | 75.3% |
| 2020 Q1 | 1.62 Million CAD | 14.22% |
| 2020 FY | 4.75 Million CAD | 13.12% |
| 2019 Q2 | 1.03 Million CAD | 24.8% |
| 2019 Q3 | 912.05 Thousand CAD | -11.96% |
| 2019 Q4 | 1.42 Million CAD | 55.91% |
| 2019 FY | 4.2 Million CAD | 27.5% |
| 2019 Q1 | 830.12 Thousand CAD | 45.43% |
| 2018 Q4 | 570.81 Thousand CAD | -43.42% |
| 2018 Q1 | 942.89 Thousand CAD | 0.89% |
| 2018 Q2 | 771.71 Thousand CAD | -18.15% |
| 2018 FY | 3.29 Million CAD | -8.69% |
| 2018 Q3 | 1 Million CAD | 30.73% |
| 2017 Q4 | 934.56 Thousand CAD | 2.68% |
| 2017 FY | 3.6 Million CAD | 34.11% |
| 2017 Q3 | 910.16 Thousand CAD | 13.21% |
| 2017 Q1 | 959.13 Thousand CAD | 88.59% |
| 2017 Q2 | 803.98 Thousand CAD | -16.18% |
| 2016 FY | 2.69 Million CAD | 49.99% |
| 2016 Q4 | 508.57 Thousand CAD | -18.69% |
| 2016 Q2 | 939 Thousand CAD | 52.16% |
| 2016 Q3 | 625.48 Thousand CAD | -33.39% |
| 2016 Q1 | 617.12 Thousand CAD | 32.29% |
| 2015 Q2 | 453.4 Thousand CAD | -6.7% |
| 2015 Q4 | 466.5 Thousand CAD | 20.33% |
| 2015 FY | 1.79 Million CAD | 16.06% |
| 2015 Q3 | 387.67 Thousand CAD | -14.5% |
| 2015 Q1 | 485.95 Thousand CAD | 10.73% |
| 2014 Q4 | 438.88 Thousand CAD | 33.48% |
| 2014 Q1 | 288.5 Thousand CAD | 3.0% |
| 2014 Q3 | 328.79 Thousand CAD | -32.78% |
| 2014 Q2 | 489.13 Thousand CAD | 69.54% |
| 2014 FY | 1.54 Million CAD | -4.05% |
| 2013 Q3 | 331.27 Thousand CAD | 0.52% |
| 2013 Q1 | 669.62 Thousand CAD | 62.5% |
| 2013 FY | 1.61 Million CAD | 10.02% |
| 2013 Q4 | 280.11 Thousand CAD | -15.44% |
| 2013 Q2 | 329.55 Thousand CAD | -50.79% |
| 2012 Q1 | 309.66 Thousand CAD | 2.33% |
| 2012 Q3 | 391.98 Thousand CAD | 11.93% |
| 2012 Q4 | 412.06 Thousand CAD | 5.12% |
| 2012 FY | 1.46 Million CAD | 18.51% |
| 2012 Q2 | 350.18 Thousand CAD | 13.09% |
| 2011 Q1 | 354.73 Thousand CAD | 91.34% |
| 2011 FY | 1.23 Million CAD | 32.91% |
| 2011 Q3 | 349.19 Thousand CAD | 52.68% |
| 2011 Q2 | 228.71 Thousand CAD | -35.53% |
| 2011 Q4 | 302.6 Thousand CAD | -13.34% |
| 2010 Q2 | 211.32 Thousand CAD | -21.28% |
| 2010 Q1 | 268.44 Thousand CAD | 150.92% |
| 2010 Q4 | 185.39 Thousand CAD | -29.84% |
| 2010 Q3 | 264.23 Thousand CAD | 25.04% |
| 2010 FY | 929.4 Thousand CAD | 6.78% |
| 2009 FY | 870.35 Thousand CAD | -17.13% |
| 2009 Q1 | 206.09 Thousand CAD | 116.8% |
| 2009 Q4 | 106.98 Thousand CAD | -65.33% |
| 2009 Q2 | 248.71 Thousand CAD | 20.68% |
| 2009 Q3 | 308.56 Thousand CAD | 24.06% |
| 2008 Q1 | 212.55 Thousand CAD | -26.75% |
| 2008 FY | 1.05 Million CAD | -0.19% |
| 2008 Q4 | 95.06 Thousand CAD | -74.97% |
| 2008 Q3 | 379.77 Thousand CAD | 4.66% |
| 2008 Q2 | 362.88 Thousand CAD | 70.72% |
| 2007 Q1 | 200.22 Thousand CAD | -27.17% |
| 2007 Q2 | 385.82 Thousand CAD | 92.7% |
| 2007 FY | 1.05 Million CAD | 17.89% |
| 2007 Q3 | 175.91 Thousand CAD | -54.41% |
| 2007 Q4 | 290.19 Thousand CAD | 64.96% |
| 2006 Q2 | 245.26 Thousand CAD | 53.33% |
| 2006 FY | 892.58 Thousand CAD | -13.77% |
| 2006 Q1 | 159.95 Thousand CAD | -44.05% |
| 2006 Q4 | 274.93 Thousand CAD | 29.42% |
| 2006 Q3 | 212.43 Thousand CAD | -13.39% |
| 2005 Q4 | 285.87 Thousand CAD | 10.15% |
| 2005 Q1 | 218.8 Thousand CAD | 2.3% |
| 2005 Q2 | 270.93 Thousand CAD | 23.82% |
| 2005 Q3 | 259.52 Thousand CAD | -4.21% |
| 2005 FY | 1.03 Million CAD | 68.05% |
| 2004 Q4 | 213.89 Thousand CAD | 92.09% |
| 2004 Q3 | 111.35 Thousand CAD | -27.59% |
| 2004 Q2 | 153.77 Thousand CAD | 32.64% |
| 2004 FY | 615.97 Thousand CAD | 27.75% |
| 2004 Q1 | 115.93 Thousand CAD | 89.29% |
| 2003 Q2 | 28.87 Thousand CAD | 0.0% |
| 2003 Q3 | 189.24 Thousand CAD | 555.31% |
| 2003 FY | 482.18 Thousand CAD | 0.0% |
| 2003 Q4 | 61.24 Thousand CAD | -67.64% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Arch Biopartners Inc. | 3.22 Million CAD | -7.461% |
| Covalon Technologies Ltd. | 14.36 Million CAD | 75.861% |
| Hemostemix Inc. | 2.15 Million CAD | -60.745% |
| Universal Ibogaine Inc. | 5.81 Million CAD | 40.402% |
| MedMira Inc. | 1.5 Million CAD | -129.683% |
| Marvel Biosciences Corp. | 2.31 Million CAD | -49.502% |
| NervGen Pharma Corp. | 17.77 Million CAD | 80.498% |
| XORTX Therapeutics Inc. | 6.38 Million CAD | 45.677% |